Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase\u00e2 $ 3 BEACON CRC test

.Competing enthusiasms.S.K.: Supply as well as Various Other Ownership Passions: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Role: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Health, Bicara Rehabs, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Undertaking BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Analysis Funding: Amgen (Inst), Variety BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Employment: Formerly Pfizer. Sell and Other Ownership Rate Of Interests: Pfizer. J.P.: Job: Formerly Pfizer. Stock and Various Other Ownership Interests: Pfizer. F.C.: Consulting or even Advisory Task: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Investigation Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Role: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Research Study Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Duty: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Role: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Analysis Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Study Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Employment: Pfizer. Inventory and Other Ownership Claims: Pfizer. X.Z.: Employment: Pfizer. Stock and Other Possession Interests: Pfizer. Patents, Nobilities, Various Other Patent: Johns Hopkins College. P.H.: Work: Pfizer. Inventory and Various Other Possession Interests: Pfizer. T.X.: Employment: Pfizer. Inventory and Other Ownership Claims: Pfizer. R.Y.: Consulting or Advisory Part: Assortment BioPharma/Pfizer, Mirati Therapies, Zai Lab, Amgen. Research Financing: Range BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Part: Array BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Therapies, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Pharmaceutical, Tessa Rehab, TheraMyc. Other Connection: Amgen, Selection Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health And Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Institute for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Learning Information, Sanofi-Aventis, Servier, Taiho Pharmaceutical.